Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis.

ABSTRACT:

Background

Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy.

Methodology and principal findings

We systematically searched the Medline, Embase, and Cochrane Central Register of Controlled Trials databases and reference lists of articles and proceedings of major meetings for obtaining relevant literature. All eligible trials included ACS patients who received either i.c. administration of abciximab or i.v. therapy. The primary outcome was major cardiovascular events, and secondary outcomes included total mortality, reinfarction, and any possible adverse events. Of 660 identified studies,

SUBMITTER: Wang JN 

PROVIDER: S-EPMC3585408 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature